Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLOS II: TP/TPF +/- Cetuximab in Larynx/Hypopharynx Carcinoma
NCT00508664Phase 2Completed
- Sponsor
- ClinAssess
- Start
- Jul 2007
- Primary completion
- Feb 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of cetuximab in laryngeal squamous cell carcinoma (LSCC), hypopharyngeal squamous cell carcinoma (HSCC), sponsored by ClinAssess. Started Jul 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
laryngeal squamous cell carcinoma (LSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT00508664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00508664.